The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1131
ISSUE1131
May 27, 2002
Topical Pimecrolimus (Elidel) for treatment of atopic dermatitis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Topical Pimecrolimus (Elidel) for treatment of atopic dermatitis
May 27, 2002 (Issue: 1131)
Pimecrolimus 1% cream (pim e kroe' limus; SDZ ASM 981; Elidel - Novartis) has been approved by the FDA for short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in non-immunocompromised patients at least 2 years...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.